ZyVersa Therapeutics Statistics
Share Statistics
ZyVersa Therapeutics has 2.34M shares outstanding. The number of shares has increased by -34.63% in one year.
| Shares Outstanding | 2.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 28.66% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.34M |
| Failed to Deliver (FTD) Shares | 13.35K |
| FTD / Avg. Volume | 1.06% |
Short Selling Information
The latest short interest is 45.48K, so 1.94% of the outstanding shares have been sold short.
| Short Interest | 45.48K |
| Short % of Shares Out | 1.94% |
| Short % of Float | 1.96% |
| Short Ratio (days to cover) | 0.19 |
Valuation Ratios
The PE ratio is -0.01 and the forward PE ratio is -0.25.
| PE Ratio | -0.01 |
| Forward PE | -0.25 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.08 |
| P/FCF Ratio | -0.1 |
| PEG Ratio | n/a |
Enterprise Valuation
ZyVersa Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.33, with a Debt / Equity ratio of 0.
| Current Ratio | 0.33 |
| Quick Ratio | 0.33 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 31.56 |
Financial Efficiency
Return on equity (ROE) is -8.88% and return on capital (ROIC) is -118.7%.
| Return on Equity (ROE) | -8.88% |
| Return on Assets (ROA) | -4.44% |
| Return on Capital (ROIC) | -118.7% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -14.04M |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -9.46M |
| Effective Tax Rate | 0.09 |
Stock Price Statistics
The stock price has increased by -86.45% in the last 52 weeks. The beta is 0.64, so ZyVersa Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -86.45% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 4 |
| Relative Strength Index (RSI) | 35.63 |
| Average Volume (20 Days) | 1.26M |
Income Statement
In the last 12 months, ZyVersa Therapeutics had revenue of $0 and earned -$98.30M in profits. Earnings per share was $-1089.67.
| Revenue | 0 |
| Gross Profit | -10.40K |
| Operating Income | -14.42M |
| Net Income | -98.30M |
| EBITDA | -107.74M |
| EBIT | - |
| Earnings Per Share (EPS) | -1089.67 |
Balance Sheet
The company has $3.14M in cash and $8.66K in debt, giving a net cash position of $3.13M.
| Cash & Cash Equivalents | 3.14M |
| Total Debt | 8.66K |
| Net Cash | 3.13M |
| Retained Earnings | -103.22M |
| Total Assets | 19.42M |
| Working Capital | 378.87M |
Cash Flow
In the last 12 months, operating cash flow was -$8.72M and capital expenditures -$1, giving a free cash flow of -$8.72M.
| Operating Cash Flow | -8.72M |
| Capital Expenditures | -1 |
| Free Cash Flow | -8.72M |
| FCF Per Share | -89.44 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ZVSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -103778.1% |
| FCF Yield | -354.24% |
Analyst Forecast
The average price target for ZVSA is $240, which is 22757.1% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $240 |
| Price Target Difference | 22757.1% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 26, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Apr 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 11.81 |
| Piotroski F-Score | 2 |